ADTX ADITXT INC US FDA Inspections 8-K Filing 2025 - Clinical Study Update On April 18, 2025, Aditxt, Inc. provided a weekly update discussing its subsidiary Pearsanta's recent approval to start clinical studies for a blood test for endometriosis. The update was presented by CEO Amro Albanna and Director of Clinical Trials Steve Varvel.Get access to all SEC 8-K filings of the ADITXT INC